Tarsons Products Limited · NSE:TARSONS
Tarsons Products — Q2 FY27 Earnings Presentation
32 slides from Tarsons Products's earnings presentation, Nov 13, 2026
Slide 1: Stock exchange covering letter for investor presentation
An ISO 9001 & ISO 13485 Certified Company Date: November 13, 2026 To, To, BSE Limited (“BSE”), National Stock Exchange of India Limited (“NSE”) Corporate Relationship Department, “Exchange Plaza”, 5th Floor, 2nd Floor, New Trading Ring, Plot No. C/1, G Block, P.J. Towers, Dalal Street, Bandra-Kurla
Slide 2: Tarsons Products Limited Investor Presentation November 2026
TARSONS PRODUCTS LIMITED Investor Presentation November 2026 TRUST DELIVERED
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Tarsons Products Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secu
Slide 4: Q2 & H1 FY27 Financial & Operational Highlights
Q2 & H1 FY27 Financial & Operational Highlights
Slide 5: Q2 & H1 FY27 Consolidated Revenue Break-up
Q2 & H1 FY27 Consolidated Revenue Break-up Standalone Domestic Standalone Export Revenue Nerbe Revenue Total Consolidated Revenue Revenue (in ₹ crs) (in ₹ crs) (in ₹ crs) (in ₹ crs) +33% +18% +13% +21% 65.2 121.2 47.5 233.9 102.8 +37% 41.9 +19% 49.0 +21% 193.7 +7% 64.9 35.3 23.4 123.7 54.7 25.8 21.8
Slide 6: Q2 & H1 FY27 Standalone Financial Highlights
Q2 & H1 FY27 Standalone Financial Highlights Revenue (in ₹ crs) Gross Profit (in ₹ crs) EBITDA (in ₹ crs) 72.8% 67.3% 72.2% 67.2% 32.5% 30.5% 31.9% 29.4% +23% +14% +13% 186.4 125.2 54.7 151.8 109.5 48.4 +25% +15% +17% 100.2 67.4 30.6 80.5 58.6 26.1 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1
Slide 7: Q2 & H1 FY27 Consolidated Financial Highlights
Q2 & H1 FY27 Consolidated Financial Highlights Revenue (in ₹ crs) Gross Profit (in ₹ crs) EBITDA (in ₹ crs) 67.5% 63.8% 72.2% 67.2% 26.8% 25.1% 26.9% 24.4% +21% +15% +9% 233.9 150.4 57.1 131.2 52.1 +21% 193.7 +13% +14% 123.7 78.9 27.4 31.1 102.3 69.1 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26
Slide 8: Bridge between Standalone & Consolidated PAT – H1FY27
Bridge between Standalone & Consolidated PAT – H1FY27 (In Rs. Crs) 3.8 -2.0 -2.1 0.1 -1.5 -1.8 Standalone PAT SBLC Commission Interest paid to Elimination of Nerbe PAT Consolidated PAT booked in Tarsons bank by subsidiary Amortisation books, eliminated on intangible on consolidation assets acquired
Slide 9: Management Commentary
Management Commentary Commenting on the performance, Mr. Aryan Sehgal, Promoter and Whole time Director of Tarsons, said: We are pleased to report 25% standalone and 21% consolidated YoY revenue growth in Q2 FY27, driven by deeper customer penetration and improving underlying demand. Customer enquir
Slide 10: Q2 & H1 FY27 Standalone Profit & Loss Statement
Q2 & H1 FY27 Standalone Profit & Loss Statement Particulars (in ₹ cr) Q2FY27 Q2FY26 Y-o-Y H1FY27 H1FY26 Y-o-Y Revenue from Operations 100.2 80.5 24.5% 186.4 151.8 22.8% Cost of Goods Sold 32.8 21.9 61.1 42.3 Gross Profit 67.4 58.6 15.0% 125.2 109.5 14.4% Gross Margin (%) 67.3% 72.8% -560 bps 67.2% 7
Slide 11: Q2 & H1 FY27 Consolidated Profit & Loss Statement
Q2 & H1 FY27 Consolidated Profit & Loss Statement Particulars (in ₹ cr) Q2FY27 Q2FY26 Y-o-Y H1FY27 H1FY26 Y-o-Y Revenue from Operations 123.7 102.3 20.8% 233.9 193.7 20.8% Cost of Goods Sold 44.8 33.2 83.5 62.5 Gross Profit 78.9 69.1 14.2% 150.4 131.2 14.7% Gross Margin (%) 63.8% 67.5% -370 bps 64.3
Slide 12: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (in Rs. Crs) Sep-26 Mar-26 Equity & Liabilities (in Rs. Crs) Sep-26 Mar-26 Non-Current Assets 905.2 920.1 Total Equity 633.1 634.7 Property, Plant & Equipment 645.2 656.8 Share Capital 10.6 10.6 Capital WIP 167.7 158.6 Other Equity 622.5 624.0 Right of Use Assets 14
Slide 13: Abridged Consolidated Cash Flow Statement
Abridged Consolidated Cash Flow Statement Particulars (in Rs. Crs) H1FY27 H1FY26 Net Profit Before Tax -0.7 8.6 Adjustments for: Non -Cash Items / Other Investment or Financial Items 62.8 46.3 Operating profit before working capital changes 62.2 55.0 Changes in working capital -8.3 -6.6 Cash generat
Slide 14: About Tarsons
TER SOMms ee SSGSSCS SS SSCS S ecm
Slide 15: Tarsons – at a Glance
Tarsons – at a Glance One of the leading Indian labware company engaged in the designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop equipment & instruments) Products used in laboratories across research organizations, academia institutes, pharm
Slide 16: Our Journey
Our Journey Product portfolio Pioneered the first Established expansion & adding Commenced fully robotic clean manufacturing facility Established line for depth in existing production of Pipette room expanding into PCR products in Jalan product basket Tips, thereby creating plant for production of f
Slide 17: Leading Indian Labware Supplier
Leading Indian Labware Supplier Trusted Brand for high quality Expertise in production of a wide range Ability to offer differentiated, user products in the plastic labware of labware products & amongst the friendly, reliable quality & cost-effective market with 40+ years vintage in the top 3 player
Slide 18: Our Competitive Edge
Our Competitive Edge Geographical Presence Brand & Quality Wide geographic reach through a Leading Indian supplier to the life sciences strong sales & distribution sector with strong brand recognition and network high-quality diversified products across varied customer segments. 03 04 State of Art F
Slide 19: Catering to diversified End User Industry
Catering to diversified End User Industry… Measures to strengthen customer relations Academic Institutes National Centre Indian Institute of Rain Forest KIIT Regular Feedback from Customers on quality, & Research for Biological Chemical Research Institute University 1 delivery & cost Sciences Techno
Slide 20: Our State-of-the-art Manufacturing Facilities
Our State-of-the-art Manufacturing Facilities… Key Highlights of the High Precision Manufacturing Process ✓ Vertically integrated manufacturing capabilities with design & development being carried out in- house ✓ Automated manufacturing with use of robotics & other technologies developed in collabor
Slide 21: Widespread Domestic Sales & Distribution network
…with widespread Domestic Sales & Distribution network… Comprehensive Pan-India Distribution Network Long-standing relationships with Distributors North: 16% of FY26 Domestic Sales East: 13% of FY26 Domestic Sales 43 Distributors 46 Distributors West: 29% of FY26 Domestic Sales 23 Distributors South
Slide 22: Huge Underlying Export Market Potential
…with huge underlying Export Market Potential… Huge Export Opportunity Market One of the very few players to have a Global Reach ✓ As of 31st March 2026, the company sold its products to 40+ countries via 45+ distributors Demand for plasticware expected to grow at 10% CAGR for developing ✓ Export op
Slide 23: Wide Range of High-Quality Products
…offering Wide Range of High-Quality Products… Our products are made from high-quality medical grade DMF registered resins which are selected to minimize additives & reduce potential leachable Consumables Reusables Others 58.9% of FY26 38.1% of FY26 3.0% of FY26 Revenue Revenue Revenue • Portfolio o
Slide 24: Diversified product portfolio of Plastic Labware
…diversified product portfolio of Plastic Labware Centrifuge Sterile Media Pipette Tips Petri Dishes Cryo Vials Storage Vials Serological Pipette Tubes Bottles Consumables (59% of FY26 Sales) • Mostly used in culture Designed for use Disposable pipettes Suited to preparation Used for storage of Perf
Slide 25: Foraying into cell culture segment
…foraying into cell culture segment Cell Culture Flask Cell Culture Plates Cell Culture Dishes Roller Bottles Support efficient and scalable cell culture Used to grow and maintain cells in a Used to grow and maintain cells in a applications. The smooth wall design controlled environment for research
Slide 26: Participation at Domestic Exhibition
Participation at Domestic Exhibition Analytica India (Hyderabad, Sep ’26)
Slide 27: Participation at International Exhibitions
Participation at International Exhibitions Analytica Germany 2026 WHX Dubai 2026
Slide 28: Key Business Strategies
Key Business Strategies • Focus on branding & promotion to enhance visibility in the labware industry to increase brand awareness & loyalty • Manufacture New Products in the cell culture & robotic handled consumables and expand Enhance existing & expand into the import dominated markets of these pro
Slide 29: Experienced Board of Director & Managerial Team
Experienced Board of Director & Managerial Team Ramanathan Subramanian Suresh Prabhala Sanjive Sehgal Non-Executive Director Arun Kumar Chairman & Managing Director Non-Executive Nominee Director • Co-founder & Managing Partner at ADV Partners. • Partner & COO at ADV Partners with 25+ • Promoter, Ch
Slide 30: ESG
Contribution towards Environmental, Social & Governance Clean room conditions eliminates all chances of NO litigations faced for pollution or contamination Use of Medical Grade degradation of environment over the Plastics. Products are designed to past five years Productivity optimisation with use o
Slide 31: Key Takeaways
Key Takeaways Leading Indian manufacturer of labware with an established brand Financial profile with historically & focus on high-quality products healthy EBITDA margin Presence in an industry with Highly automated state-of-the-art double-digit growth potential and manufacturing facilities churning
Slide 32: Thank You
Thank You Tarsons Products Limited Strategic Growth Advisors Private Limited CIN: L51109WB1983PLC036510 CIN: U74140MH2010PTC204285 Mr. Santosh Agarwal – Chief Financial Officer Mr. Sagar Shroff / Mr. Tanay Shah santosh@tarsons.in sagar.shroff@sgapl.net / tanay.shah@sgapl.net +91 98205 19303 / +91 98